Reflections on Clinical Impact and Future Data Needs

This closing segment explores the broader implications of LITESPARK-011 for clinical practice and future research. The discussion considers how belzutifan-based combinations may fit into treatment sequencing, particularly in relation to existing options. Factors such as cost, access, toxicity, and patient selection are highlighted as key considerations for adoption. The speakers also emphasize the need for additional data, including mature overall survival results and further studies evaluating HIF-2α inhibition in earlier lines of therapy. The segment concludes by reflecting on the evolving landscape of RCC treatment and the importance of continued research to refine therapeutic strategies and improve patient outcomes.